BeiGene has announced that its Tevimbra (tislelizumab) has been approved by the European Commission (EC) as part of a ...

Sino-American biotech BeiGene (Nasdaq: ONC; HKEX 06160) today announced that the European Commission has approved Tevimbra ...

BeiGene has decided to stop the development ... advanced PD-L1-positive non-small cell lung cancer (NSCLC). "We evaluate our clinical programmes to focus our resources on the most promising ...

BeiGene, Ltd., soon to be BeOne Medicines ... Tevimbra to treat nasopharyngeal cancer (in the EU), non-small cell lung cancer (in the EU), and gastric cancer (in Japan), with news expected ...

BeiGene (NASDAQ:ONC) is scheduled to announce Q1 earnings results on Wednesday, May 7th, before market open. The consensus EPS Estimate is -$0.74 and the consensus Revenue Estimate is $1.14B (+51.7% Y ...

BeiGene is the only company with an internally ... marking another milestone in our targeted lung cancer therapy portfolio. This year, we anticipate more than 10 proof-of-concept readouts across ...

In April 2025, our partner Jazz announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of ...

The Swiss pharma group is paying BeiGene $300 million upfront for an option on ociperlimab, a TIGIT antibody in phase 3 testing for non-small cell lung cancer (NSCLC), with another $700 million on ...

Six posters presented at the American Association for Cancer Research (AACR) annual meetingAppointment of Dr. Sabeen Mekan as Senior Vice President, Clinical DevelopmentReported $321.6 million in cash ...

During a live event, Krish Patel, MD, surveyed participants on using bispecific T-cell engagers vs loncastuximab in a patient ...

A trial testing the combination of the anti-TIGIT antibody tiragolumab and atezolizumab vs atezolizumab in previously untreated programmed cell death ligand 1 (PD-L1)–high locally advanced ...